Deubiquitination in prostate cancer progression: role of USP22

Abstract

Prostate cancer (PCa) is the leading cause of cancer death in men. With more therapeutic modalities available, the overall survival in PCa has increased significantly in recent years. Patients with relapses after advanced second-generation anti-androgen therapy however, often show poor disease prognosis. This group of patients often die from cancer-related complicacies. Multiple approaches have been taken to understand disease recurrence and to correlate the gene expression profile. In one such study, an 11-gene signature was identified to be associated with PCa recurrence and poor survival. Amongst them, a specific deubiquitinase called ubiquitin-specific peptidase 22 (USP22) was selectively and progressively overexpressed with PCa progression. Subsequently, it was shown to regulate androgen receptors and Myc, the two most important regulators of PCa progression. Furthermore, USP22 has been shown to be associated with the development of therapy resistant PCa. Inhibiting USP22 was also found to be therapeutically advantageous, especially in clinically challenging and advanced PCa. This review provides an update of USP22 related functions and challenges associated with PCa research and explains why targeting this axis is beneficial for PCa relapse cases.

Keywords

USP22 / prostate cancer / SAGA / Deubiquitin

References

[1] Siegel RL,Wender RC,Ma J.An assessment of progress in cancer control..CA Cancer J Clin2018;68:329-39

[2] Rathkopf DE,Shore ND,Alumkal JJ.Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone..Clin Cancer Res2017;23:3544-51 PMCID:PMC5543693

[3] Rathkopf DE,Ryan CJ,Shore ND.Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide..Ann Oncol2017;28:2264-71 PMCID:PMC5834046

[4] Scher HI,Saad F,Sternberg CN.Increased survival with enzalutamide in prostate cancer after chemotherapy..N Engl J Med2012;367:1187-97

[5] Zhou CK,Lortet-Tieulent J,Jemal A.Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group..Int J Cancer2016;138:1388-400 PMCID:PMC4712103

[6] Berish RB,Telmer PG,Leong HS.Translational models of prostate cancer bone metastasis..Nat Rev Urol2018;15:403-21

[7] Clarke NW,Brown MD.Molecular mechanisms of metastasis in prostate cancer..Asian J Androl2009;11:57-67 PMCID:PMC3735202

[8] Yoshida T,Taniguchi H,Sugi M.A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the prevention of osteopenia with minodronate and denosumab (PROMADE) study..Osteoporos Int2020;31:1251-9

[9] Deantoni CL,Cozzarini C,Brombin C.Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases..Br J Radiol2020;93:20190353

[10] DiNatale A.The bone microenvironment in prostate cancer metastasis..Adv Exp Med Biol2019;1210:171-84

[11] Wang L,Kao CY,Tsai MJ.Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1..J Clin Invest2020;130:1782-92 PMCID:PMC7108891

[12] Ku SY,Wang Y,Seshadri M.Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance..Science2017;355:78-83 PMCID:PMC5367887

[13] Mu P,Benelli M,Hoover E.SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer..Science2017;355:84-8 PMCID:PMC5247742

[14] Jaratlerdsiri W,Gong T,Kalsbeek AMF.Whole-genome sequencing reveals elevated tumor mutational burden and initiating driver mutations in african men with treatment-naive, high-risk prostate cancer..Cancer Res2018;78:6736-46

[15] Zolotovskaia MA,Petrov IV,Moiseev AA.Disparity between inter-patient molecular heterogeneity and repertoires of target drugs used for different types of cancer in clinical oncology..Int J Mol Sci2020;21: PMCID:PMC7084891

[16] Su X,Bo J,Zhao LN.Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma..Prostate2020;80:508-17

[17] Glinsky GV,Glinskii AB.Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer..J Clin Invest2005;115:1503-21 PMCID:PMC1136989

[18] Schrecengost RS,Goodwin JF,Urban MW.USP22 regulates oncogenic signaling pathways to drive lethal cancer progression..Cancer Res2014;74:272-86 PMCID:PMC3947329

[19] McCann JJ,Poudel Neupane N,McNair C.USP22 functions as an oncogenic driver in prostate cancer by regulating cell proliferation and DNA Repair..Cancer Res2020;80:430-43

[20] Pfoh R,Georges AA,Zheng H.Crystal structure of USP7 ubiquitin-like domains with an ICP0 peptide reveals a novel mechanism used by viral and cellular proteins to target USP7..PLoS Pathog2015;11:e1004950 PMCID:PMC4457826

[21] Reyes-Turcu FE,Wilkinson KD.Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes..Annu Rev Biochem2009;78:363-97 PMCID:PMC2734102

[22] Sahtoe DD.Layers of DUB regulation..Trends Biochem Sci2015;40:456-67

[23] Espinosa JM.Histone H2B ubiquitination: the cancer connection..Genes Dev2008;22:2743-9 PMCID:PMC2751279

[24] Poondla N,Kim KS.Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?.BMB Rep2019;52:181-9 PMCID:PMC6476481

[25] Melo-Cardenas J,Zhang DD.Ubiquitin-specific peptidase 22 functions and its involvement in disease..Oncotarget2016;7:44848-56 PMCID:PMC5190139

[26] Fraile JM,Rodriguez D,Lopez-Otin C.Deubiquitinases in cancer: new functions and therapeutic options..Oncogene2012;31:2373-88

[27] Atanassov BS,Multani AS,Tora L.Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance..Mol Cell2009;35:352-64 PMCID:PMC2749492

[28] Ramachandran S,Li C,Ling AK.The SAGA Deubiquitination Module Promotes DNA Repair and Class Switch Recombination through ATM and DNAPK-Mediated gammaH2AX Formation..Cell Rep2016;15:1554-65 PMCID:PMC4888775

[29] Armour SM,Braun CR,McMahon SB.A high-confidence interaction map identifies SIRT1 as a mediator of acetylation of USP22 and the SAGA coactivator complex..Mol Cell Biol2013;33:1487-502 PMCID:PMC3624249

[30] Young MJ,Lin TE,Hung JJ.The role of ubiquitin-specific peptidases in cancer progression..J Biomed Sci2019;26:42 PMCID:PMC6537419

[31] Zhang Y,Zhang X,Wang L.Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer..J Cancer Res Clin Oncol2011;137:1245-53

[32] Daniel JA.Multi-tasking on chromatin with the SAGA coactivator complexes..Mutat Res2007;618:135-48 PMCID:PMC1892243

[33] Koehler C,Stierle M,Devys D.DNA binding by Sgf11 protein affects histone H2B deubiquitination by Spt-Ada-Gcn5-acetyltransferase (SAGA)..J Biol Chem2014;289:8989-99 PMCID:PMC3979380

[34] Henry KW,Lo WS,Emre NC.Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8..Genes Dev2003;17:2648-63 PMCID:PMC280615

[35] Henry KW.Trans-tail histone modifications: wedge or bridge?.Nat Struct Biol2002;9:565-6

[36] Zhao Y,Ito S,Metzger E.A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing..Mol Cell2008;29:92-101

[37] Ao N,Feng H,Li Z.Ubiquitin-specific peptidase USP22 negatively regulates the STAT signaling pathway by deubiquitinating SIRT1..Cell Physiol Biochem2014;33:1863-75

[38] Lin Z,Kong Q,Lee SM.USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development..Mol Cell2012;46:484-94

[39] Kobayashi T,Takashima K,Kosodo Y.Deubiquitinating enzymes regulate Hes1 stability and neuronal differentiation..FEBS J2015;282:2411-23

[40] Gao Y,Xu P,Chen Z.USP22 is a positive regulator of NFATc2 on promoting IL2 expression..FEBS Lett2014;588:878-83

[41] Xiao H,Yang Y,Xie X.USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell lung cancer..Biochem Biophys Res Commun2015;460:703-8

[42] Wilson MA,Hirsch C,Schibler A.Ubp8 and SAGA regulate Snf1 AMP kinase activity..Mol Cell Biol2011;31:3126-35 PMCID:PMC3147604

[43] Kim D,Park HI,Yoo L.Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells..J Cell Physiol2017;232:3664-76

[44] Atanassov BS.USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1..EMBO Rep2011;12:924-30 PMCID:PMC3166460

[45] Li C,So CC,Du L.The H2B deubiquitinase Usp22 promotes antibody class switch recombination by facilitating non-homologous end joining..Nat Commun2018;9:1006 PMCID:PMC5843634

[46] Xiong J,Li X,Gong Z.Cloning and characterization of the human USP22 gene promoter..PLoS One2012;7:e52716 PMCID:PMC3530469

[47] Xiong J,Gong Z,Zhang C.PKA/CREB regulates the constitutive promoter activity of the USP22 gene..Oncol Rep2015;33:1505-11

[48] Gennaro VJ,Peck AR,Wang F.Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells..Proc Natl Acad Sci U S A2018;115:E9298-307 PMCID:PMC6176615

[49] Piao S,Hu J,Ma J.USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma..PLoS One2012;7:e42540 PMCID:PMC3411815

[50] Hu J,Piao SL,Yang YM.Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer..Lung Cancer2012;77:593-9

[51] Yang M,Wang YY,Ge TT.Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics..Tumour Biol2014;35:929-34

[52] Wang A,Lu C,Liang J.USP22 induces cisplatin resistance in lung adenocarcinoma by regulating gammaH2AX-mediated DNA damage repair and Ku70/Bax-mediated apoptosis..Front Pharmacol2017;8:274 PMCID:PMC5434448

[53] Liu YL,Xu H.Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer..J Surg Oncol2011;103:283-9

[54] Lang G,Umlauf D,Koffler J.The tightly controlled deubiquitination activity of the human SAGA complex differentially modifies distinct gene regulatory elements..Mol Cell Biol2011;31:3734-44 PMCID:PMC3165722

[55] Zhang K,Wang J,Guo Y.Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer..Cell Commun Signal2019;17:167 PMCID:PMC6916027

[56] Lin Z,Qiu Q,Yang H.Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1..Cell Discov2015;1: PMCID:PMC4809424

[57] Ma Y,Wang Z,Ni J.USP22 maintains gastric cancer stem cell stemness and promotes gastric cancer progression by stabilizing BMI1 protein..Oncotarget2017;8:33329-42 PMCID:PMC5464871

[58] Qiu GZ,Wang XG,Zhao T.Hypoxia-induced USP22-BMI1 axis promotes the stemness and malignancy of glioma stem cells via regulation of HIF-1alpha..Life Sci2020;247:117438

[59] Ning J,Liu W,Xue Y.Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer..Eur J Histochem2012;56:e46 PMCID:PMC3567765

[60] Liang JX,Gao W,Wang AM.Ubiquitinspecific protease 22induced autophagy is correlated with poor prognosis of pancreatic cancer..Oncol Rep2014;32:2726-34

[61] Kosinsky RL,Zerche M,Dyas A.USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer..Cell Death Dis2019;10:911 PMCID:PMC6892875

[62] Yang DD,Sun LY,Huang Q.The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma..Cell Biochem Biophys2011;61:703-10

[63] Yuan X,Xu A,Zhan Y.Ubiquitin-specific peptidase 22 promotes proliferation and metastasis in human colon cancer..Oncol Lett2019;18:5567-76 PMCID:PMC6781658

[64] Tang B,Li B,Xu Q.High USP22 expression indicates poor prognosis in hepatocellular carcinoma..Oncotarget2015;6:12654-67 PMCID:PMC4494964

[65] Wang H,Chen JH,Wang L.Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma..Tumour Biol2013;34:1635-9

[66] Hong A,Chung KC.Ubiquitin-specific protease 22 (USP22) positively regulates RCAN1 protein levels through RCAN1 de-ubiquitination..J Cell Physiol2015;230:1651-60

[67] Zhou D,Sun DW,Hu J.USP22 down-regulation facilitates human retinoblastoma cell aging and apoptosis via inhibiting TERT/P53 pathway..Eur Rev Med Pharmacol Sci2017;21:2785-92

[68] Melo-Cardenas J,Wei J,Kong S.USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism..Blood2018;132:423-34 PMCID:PMC6071563

[69] Kosinsky RL,Saul D,Wohn L.USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity..Cell Death Differ2020;27:1328-40 PMCID:PMC7205880

[70] Cato L,Lee I,Coleman I.ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer..Cancer Cell2019;35:401-13.e6 PMCID:PMC7246081

[71] Sharp A,Yuan W,Dolling D.Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer..J Clin Invest2019;129:192-208 PMCID:PMC6307949

[72] Abida W,Heller G,Armenia J.Genomic correlates of clinical outcome in advanced prostate cancer..Proc Natl Acad Sci U S A2019;116:11428-36 PMCID:PMC6561293

[73] Welsh JB,Su AI,Wang-Rodriguez J.Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer..Cancer Res2001;61:5974-8

[74] Holzbeierlein J,LaTulippe E,Satagopan J.Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance..Am J Pathol2004;164:217-27 PMCID:PMC1602218

[75] Grasso CS,Robinson DR,Dhanasekaran SM.The mutational landscape of lethal castration-resistant prostate cancer..Nature2012;487:239-43 PMCID:PMC3396711

[76] Nelson WG,Yegnasubramanian S.USP2a activation of MYC in prostate cancer..Cancer Discov2012;2:206-7 PMCID:PMC4479124

[77] Priolo C,Brahamandan M,Sicinska E.The isopeptidase USP2a protects human prostate cancer from apoptosis..Cancer Res2006;66:8625-32

[78] Morra F,Napolitano V,Miro C.The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells..Oncotarget2017;8:31815-29 PMCID:PMC5458250

[79] Wang Z,You Y,Ren H.USP7: novel drug target in cancer therapy..Front Pharmacol2019;10:427 PMCID:PMC6502913

[80] Lu Y,Chevalier S.Identification of distinctive patterns of USP19-mediated growth regulation in normal and malignant cells..PLoS One2011;6:e15936 PMCID:PMC3022023

[81] Chu IM,Slingerland JM.The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy..Nat Rev Cancer2008;8:253-67

[82] McClurg UL,Dransfield DT,Chit N.The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival..Oncotarget2018;9:24992-5007 PMCID:PMC5982776

[83] Geng L,Zhang M.Ubiquitin-specific protease 14 promotes prostate cancer progression through deubiquitinating the transcriptional factor ATF2..Biochem Biophys Res Commun2020;524:16-21

[84] Dirac AM.The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling..Mol Cancer Res2010;8:844-54

[85] Guo F,Wang F,Shi X.Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer..Cell Death Differ2019;doi: 10.1038/s41418-019-0473-8 PMCID:PMC7244590

[86] Zhang J,Luan T,Chen J.Deubiquitinase USP9X regulates the invasion of prostate cancer cells by regulating the ERK pathway and mitochondrial dynamics..Oncol Rep2019;41:3292-304 PMCID:PMC6489063

[87] Zhou X,Liu J,Wang T.Pirarubicin reduces USP22 expression by inhibiting CREB-1 phosphorylation in HeLa cells..Exp Ther Med2019;17:4230-6 PMCID:PMC6468931

[88] de Las Pozas A,De Cesare V,Perez-Stable C.Inhibiting Multiple Deubiquitinases To Reduce Androgen Receptor Expression In Prostate Cancer Cells..Sci Rep2018;8:13146 PMCID:PMC6120934

[89] Chauhan D,Nicholson B,Zhou B.A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance..Cancer Cell2012;22:345-58 PMCID:PMC3478134